| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1026993418 |
| P356 | DOI | 10.1054/BJOC.2001.1796 |
| P932 | PMC publication ID | 2363645 |
| P698 | PubMed publication ID | 11355958 |
| P5875 | ResearchGate publication ID | 11981931 |
| P50 | author | Dan W Zaharevitz | Q47455673 |
| P2093 | author name string | E A Sausville | |
| S Arbuck | |||
| S Decker | |||
| J M Venditti | |||
| M Christian | |||
| L V Rubinstein | |||
| J I Johnson | |||
| D Zaharevitz | |||
| M Hollingshead | |||
| S Kalyandrug | |||
| S Schepartz | |||
| P2860 | cites work | A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases | Q28140411 |
| Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA. | Q33814833 | ||
| Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay | Q34661407 | ||
| Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions | Q40203523 | ||
| Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines | Q41679901 | ||
| Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts | Q46293402 | ||
| Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm | Q52526450 | ||
| Preclinical drug development: rationale and methods | Q71055218 | ||
| History of the Cancer Chemotherapy Program | Q71190437 | ||
| Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy | Q73078401 | ||
| Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs | Q77669968 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1424-1431 | |
| P577 | publication date | 2001-05-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials | |
| P478 | volume | 84 |
| Q35428655 | 3D tissue-engineered model of Ewing's sarcoma |
| Q35624169 | A Framework to Select Clinically Relevant Cancer Cell Lines for Investigation by Establishing Their Molecular Similarity with Primary Human Cancers |
| Q28659265 | A Review of the Institute of Medicine’s Analysis of using Chimpanzees in Biomedical Research |
| Q89629384 | A T CELL REDIRECTING BISPECIFIC G-PROTEIN COUPLED RECEPTOR CLASS 5 MEMBER DxCD3 ANTIBODY TO TREAT MULTIPLE MYELOMA |
| Q96609469 | A clinically and genomically annotated nerve sheath tumor biospecimen repository |
| Q41658087 | A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option |
| Q28606538 | A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib |
| Q37225229 | A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model |
| Q33869944 | A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock |
| Q37139435 | A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins |
| Q61812187 | A potential novel therapy for FGFR1-amplified pancreatic cancer with bone metastasis, screened by next-generation sequencing and a patient-derived xenograft model |
| Q24647698 | A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro |
| Q37021789 | A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models |
| Q36889620 | A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation. |
| Q34143251 | A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening. |
| Q64103643 | A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors |
| Q59326990 | A systematic review of the validity of patient derived xenograft (PDX) models: the implications for translational research and personalised medicine |
| Q46060618 | Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro |
| Q39663467 | Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr–Abl positive cell lines in vitro and in vivo |
| Q55237889 | Advances in prostate cancer research models: From transgenic mice to tumor xenografting models. |
| Q38107967 | Advances in the development and use of human tissue-based techniques for drug toxicity testing |
| Q48312920 | Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics |
| Q26772895 | An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts |
| Q34250295 | An improved syngeneic orthotopic murine model of human breast cancer progression |
| Q85909830 | An orthotopic xenograft model with survival hindlimb amputation allows investigation of the effect of tumor microenvironment on sarcoma metastasis |
| Q90043616 | Animal Models to Study Cancer and Its Microenvironment |
| Q28710144 | Animal models and conserved processes |
| Q36093956 | Animal models for exploring the pharmacokinetics of breast cancer therapies |
| Q35838120 | Animal models of human colorectal cancer: Current status, uses and limitations |
| Q27022321 | Antibody Drug Conjugates: Preclinical Considerations |
| Q39339582 | Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response |
| Q37002288 | Antitumor efficacy testing in rodents |
| Q44328527 | Apoptosis enzyme-linked immunosorbent assay distinguishes anticancer drugs from toxic chemicals and predicts drug synergism |
| Q28478248 | Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases |
| Q37030878 | Aurora kinase inhibitors: identification and preclinical validation of their biomarkers |
| Q48022350 | Aurora kinases dawn as cancer drug targets |
| Q37236624 | Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. |
| Q37715399 | Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer |
| Q36115985 | Balancing safety, effectiveness, and public desire: the FDA and cancer |
| Q37561973 | Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance |
| Q36123789 | Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods |
| Q26770495 | Bioengineering Models for Breast Cancer Research |
| Q46390752 | Biological therapy for pediatric malignancy: current perspectives |
| Q92503481 | CSCs in Breast Cancer-One Size Does Not Fit All: Therapeutic Advances in Targeting Heterogeneous Epithelial and Mesenchymal CSCs |
| Q91711327 | Canine Cancer: Strategies in Experimental Therapeutics |
| Q37984855 | Canine tumors: a spontaneous animal model of human carcinogenesis |
| Q46662292 | Capsaicin inhibits proliferation of endometriotic cells in vitro |
| Q47572273 | Cell and Tissue Biology Paves a Path to Breast Cancer Prevention |
| Q37714306 | Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents |
| Q90212189 | Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy |
| Q36070093 | Challenges in pre-clinical testing of anti-cancer drugs in cell culture and in animal models |
| Q48242134 | Characterization of an Orthotopic Colorectal Cancer Mouse Model and Its Feasibility for Accurate Quantification in Positron Emission Tomography |
| Q97522508 | Characterization of multicellular breast tumor spheroids using image data-driven biophysical mathematical modeling |
| Q36340652 | Childhood acute lymphoblastic leukaemia and relapse |
| Q36900063 | Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment |
| Q89859445 | Choosing The Right Animal Model for Renal Cancer Research |
| Q33916974 | Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-adrenergic signaling in the pancreatic microenvironment. |
| Q90620231 | Clinical Implementation of Precision Medicine in Gastric Cancer |
| Q28076891 | Combination therapeutics in complex diseases |
| Q39131426 | Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line |
| Q37352783 | Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells |
| Q37314382 | Comparison of antiplatelet activity of garlic tablets with cardio-protective dose of aspirin in healthy volunteers: a randomized clinical trial |
| Q42222417 | Comparison of serum and tissue levels of trace elements in different models of cervical cancer |
| Q38765553 | Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line |
| Q53208031 | Compressing drug development timelines in oncology using phase '0' trials |
| Q26781215 | Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies |
| Q101356068 | Cucurbitacin Mediated Regulation of Deregulated Oncogenic Signaling Cascades and Non-coding RNAs in Different Cancers: Spotlight on JAK/STAT, Wnt/β-catenin, mTOR, TRAIL-mediated pathways |
| Q97525785 | Culture and application of conditionally reprogrammed primary tumor cells |
| Q38689944 | Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research |
| Q33667686 | Current status and perspectives of patient-derived xenograft models in cancer research |
| Q34483343 | Cytotoxicity, Toxicity, and Anticancer Activity of Zingiber Officinale Roscoe Against Cholangiocarcinoma |
| Q33706073 | Delphinidin attenuates neoplastic transformation in JB6 Cl41 mouse epidermal cells by blocking Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling |
| Q38351132 | Delta(9) -tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature |
| Q39710264 | Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy |
| Q34056295 | Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee |
| Q36732115 | Designing phase 0 cancer clinical trials |
| Q21131727 | Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy |
| Q53342271 | Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue |
| Q30410903 | Development and characterization of xenograft model systems for adenoid cystic carcinoma |
| Q37712156 | Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma |
| Q88549076 | Development of Preclinical Models to Understand and Treat Colorectal Cancer |
| Q60048505 | Development of Severe Combined Immunodeficient (SCID) Pig Models for Translational Cancer Modeling: Future Insights on How Humanized SCID Pigs Can Improve Preclinical Cancer Research |
| Q33926659 | Development of flexible-heteroarotinoids for kidney cancer |
| Q34605253 | Developmental therapeutics program at the NCI: molecular target and drug discovery process |
| Q50237873 | Di-rhamnolipids improve effect of trehalose on both hypothermic preservation and cryopreservation of rat hepatocytes |
| Q37324241 | Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients |
| Q37829437 | Dose-toxicity models in oncology |
| Q39405855 | Early Development Challenges for Drug Products Containing Nanomaterials |
| Q26865076 | Early phase clinical trials to identify optimal dosing and safety |
| Q37286152 | Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model. |
| Q42039942 | Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer |
| Q39129359 | Elimination of ascorbic acid after high-dose infusion in prostate cancer patients: a pharmacokinetic evaluation |
| Q38180306 | Emerging advances in nanomedicine with engineered gold nanostructures |
| Q34669632 | Engineering cellular microenvironments to improve cell-based drug testing |
| Q38244936 | Engineering strategies to mimic the glioblastoma microenvironment |
| Q39037597 | Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model |
| Q26783904 | Esophageal Cancer: Insights From Mouse Models |
| Q50052157 | Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach |
| Q37588340 | Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion |
| Q36633405 | Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. |
| Q33572502 | Establishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluation. |
| Q38978618 | Establishment and characterization of an orthotopic sinonasal squamous cell carcinoma mouse model |
| Q54620098 | Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice. |
| Q91949994 | Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer |
| Q47140693 | Establishment and evaluation of four different types of patient-derived xenograft models |
| Q92092492 | Establishment of hepatocellular carcinoma patient-derived xenografts from image-guided percutaneous biopsies |
| Q34003315 | Establishment of human tumor xenografts in immunodeficient mice |
| Q41158938 | Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness. |
| Q35798580 | Establishment of patient-derived cancer xenografts in immunodeficient NOG mice |
| Q74613104 | European Organization for Research and Treatment of Cancer (EORTC) Laboratory Research Division workshop on the role of in vivo pre-clinical models in the development of contemporary cancer therapeutics, Verona, Italy, 3 February 2001 |
| Q42455524 | Evaluation of spheroid head and neck squamous cell carcinoma cell models in comparison to monolayer cultures |
| Q35921493 | Evaluation of the therapeutic efficacy of a MEK inhibitor (TAK-733) using ¹⁸F-fluorodeoxyglucose-positron emission tomography in the human lung xenograft model A549. |
| Q100295114 | Evaluation of the treatment strategies on patient-derived xenograft mice of human breast tumor |
| Q38113460 | Ex vivo culture of human prostate tissue and drug development |
| Q48500250 | Examining the utility of patient-derived xenograft mouse models |
| Q37024040 | Experimental anti-tumor therapy in 3-D: spheroids--old hat or new challenge? |
| Q34345987 | Experimental models of hepatocellular carcinoma |
| Q52332024 | Extensive and systematic rewiring of histone post-translational modifications in cancer model systems. |
| Q64108509 | Factors that influence response classifications in chemotherapy treated patient-derived xenografts (PDX) |
| Q39060269 | From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers. |
| Q28084982 | From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer? |
| Q94528700 | Frontiers in Intravital Multiphoton Microscopy of Cancer |
| Q36326358 | GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo |
| Q64101398 | Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts |
| Q34994030 | Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer |
| Q28548481 | Generation of Multicellular Tumor Spheroids with Microwell-Based Agarose Scaffolds for Drug Testing |
| Q34372342 | Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice |
| Q52927394 | Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy |
| Q37891469 | Genetically engineered mouse models of diffuse gliomas |
| Q51427440 | Genetically engineered mouse models: future tools to predict clinical trial results in oncology? |
| Q39329335 | Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue |
| Q24805062 | HLA class I and II genotype of the NCI-60 cell lines |
| Q34633249 | Hepatocellular carcinoma: insight from animal models |
| Q92553015 | High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer |
| Q86039429 | How can attrition rates be reduced in cancer drug discovery? |
| Q28553420 | Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging |
| Q38183539 | Hydrodynamic transfection for generation of novel mouse models for liver cancer research |
| Q37269137 | Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts. |
| Q35668971 | Identification of Simple Compounds with Microtubule-Binding Activity That Inhibit Cancer Cell Growth with High Potency |
| Q52327617 | Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor explants |
| Q36920226 | Illuminating Cancer Systems with Genetically Engineered Mouse Models and Coupled Luciferase ReportersIn Vivo |
| Q35903509 | Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance |
| Q56795925 | Immune system plays an important role in the success and failure of conventional cancer therapy |
| Q26766538 | Immunocompromised and immunocompetent mouse models for head and neck squamous cell carcinoma |
| Q37965556 | Improving the Outcomes: Developing Cancer Therapeutics |
| Q39915376 | In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies |
| Q55429885 | In vitro antineoplastic effects of auranofin in canine lymphoma cells. |
| Q39460944 | In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues |
| Q36083676 | In vivo toxicity and antitumor activity of essential oils extract from agarwood (Aquilaria crassna). |
| Q42678871 | Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis |
| Q39491036 | Induction of cell death by a novel naphthoquinone containing a modified anthracycline ring system |
| Q27321370 | Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenografts |
| Q29547558 | Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer |
| Q33809839 | Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide |
| Q55430418 | Integration of conventional cell viability assays for reliable and reproducible read-outs: experimental evidence. |
| Q36990233 | Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture |
| Q92635171 | Krebs Cycle Intermediate-Modified Carbonate Apatite Nanoparticles Drastically Reduce Mouse Tumor Burden and Toxicity by Restricting Broad Tissue Distribution of Anticancer Drugs |
| Q55187959 | Liquid biopsy in pancreatic cancer: the beginning of a new era. |
| Q39548990 | MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer |
| Q36741548 | Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids |
| Q34661270 | Maximizing mouse cancer models |
| Q36153295 | Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice |
| Q36488752 | Mechanisms of drug inhibition of signalling molecules |
| Q35126634 | Metastasis Suppressor Genes: Basic Biology and Potential Clinical Use |
| Q35037682 | Metastasis suppressors alter the signal transduction of cancer cells |
| Q30488255 | Metastatic behaviour of primary human tumours in a zebrafish xenotransplantation model |
| Q38891959 | Metastatic melanoma moves on: translational science in the era of personalized medicine. |
| Q35828338 | Microarray profiling shows distinct differences between primary tumors and commonly used preclinical models in hepatocellular carcinoma. |
| Q40629903 | Model organoids provide new research opportunities for ductal pancreatic cancer |
| Q36910615 | Modeling NSCLC Progression: Recent Advances and Opportunities Available |
| Q37816111 | Modeling Opportunities in Comparative Oncology for Drug Development |
| Q38827211 | Modeling head and neck cancer stem cell-mediated tumorigenesis. |
| Q36842030 | Modeling pancreatic cancer with organoids |
| Q34667643 | Modelling breast cancer: one size does not fit all. |
| Q37285542 | Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics |
| Q33274040 | Molecular characterization of putative chordoma cell lines |
| Q38740566 | Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors |
| Q36150356 | Molecular markers that predict response to colon cancer therapy |
| Q84830452 | Monoclonal Antibody Lead Characterization: In Vitro and In Vivo Methods |
| Q90221026 | Mouse Tumor-Bearing Models as Preclinical Study Platforms for Oral Squamous Cell Carcinoma |
| Q36499581 | Mouse models in oncogenesis and cancer therapy. |
| Q92059453 | Mouse models of colorectal cancer: Past, present and future perspectives |
| Q24657555 | Mouse xenograft models vs GEM models for human cancer therapeutics |
| Q33637214 | Multicellular tumor spheroids as a model for assessing delivery of oligonucleotides in three dimensions |
| Q28486451 | Multicellular tumor spheroids for evaluation of cytotoxicity and tumor growth inhibitory effects of nanomedicines in vitro: a comparison of docetaxel-loaded block copolymer micelles and Taxotere® |
| Q28541848 | Multiplexing spheroid volume, resazurin and acid phosphatase viability assays for high-throughput screening of tumour spheroids and stem cell neurospheres |
| Q24673595 | Murine models to evaluate novel and conventional therapeutic strategies for cancer |
| Q41342397 | NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations. |
| Q36143238 | NSG Mice Provide a Better Spontaneous Model of Breast Cancer Metastasis than Athymic (Nude) Mice |
| Q38915184 | Nanomedicines: From Bench to Bedside and Beyond. |
| Q34422537 | National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing |
| Q37123902 | New cast for a new era: preclinical cancer drug development revisited. |
| Q35258057 | New concepts in breast cancer genomics and genetics |
| Q33758471 | New strategies in ewing sarcoma: lost in translation? |
| Q39673894 | Next generation patient-derived prostate cancer xenograft models |
| Q37195118 | Nitric oxide and cancer therapy: the emperor has NO clothes |
| Q24293321 | Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast carcinoma cells |
| Q89781606 | Novel Breast Cancer Brain Metastasis Patient-Derived Orthotopic Xenograft Model for Preclinical Studies |
| Q38805516 | Novel immunologic tolerance of human cancer cell xenotransplants in zebrafish. |
| Q39112394 | On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach |
| Q36732058 | Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient |
| Q36565598 | Oncology Drug Development and Approval of Systemic Anticancer Therapy by the U.S. Food and Drug Administration |
| Q35549696 | Oncolytic vaccinia virus therapy of salivary gland carcinoma |
| Q37244372 | Optimized Protocol To Analyze Changes in the Lipidome of Xenografts after Treatment with 2-Hydroxyoleic Acid |
| Q89936129 | Orthotopic Implantation Achieves Better Engraftment and Faster Growth Than Subcutaneous Implantation in Breast Cancer Patient-Derived Xenografts |
| Q35914464 | Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF |
| Q37223221 | Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients |
| Q49484270 | Osteosarcoma: Accelerating Progress Makes for a Hopeful Future |
| Q36516942 | Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research |
| Q55438732 | PATIENT-DERIVED XENOGRAFTS AS A PRECLINICAL MODEL FOR BONE SARCOMAS. |
| Q38303124 | PEG-lipid micelles as drug carriers: physiochemical attributes, formulation principles and biological implication |
| Q36592961 | Patient-Derived Xenografts as a Model System for Radiation Research |
| Q93361099 | Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response |
| Q38367997 | Patient-derived bladder cancer xenografts: a systematic review. |
| Q36413247 | Patient-derived cell models as preclinical tools for genome-directed targeted therapy |
| Q34125001 | Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review |
| Q55155270 | Patient-derived tumor xenografts of lung squamous cell carcinoma alter long non-coding RNA profile but not responsiveness to cisplatin. |
| Q24604068 | Patient-derived tumour xenografts as models for oncology drug development |
| Q39057246 | Patient-derived xenograft (PDX) models in basic and translational breast cancer research. |
| Q36946697 | Patient-derived xenograft (PDX) tumors increase growth rate with time. |
| Q57091941 | Patient-derived xenograft cryopreservation and reanimation outcomes are dependent on cryoprotectant type |
| Q35568077 | Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements |
| Q52311090 | Patient-derived xenograft models in musculoskeletal malignancies. |
| Q27026531 | Patient-derived xenograft models of breast cancer and their predictive power |
| Q34205518 | Patient-derived xenograft models: an emerging platform for translational cancer research |
| Q50027944 | Patient-derived xenografts as preclinical neuroblastoma models |
| Q38741974 | Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments. |
| Q35884941 | Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells |
| Q33801384 | Personalising pancreas cancer treatment: When tissue is the issue |
| Q91162952 | Personalized Cancer Models for Target Discovery and Precision Medicine |
| Q52683931 | Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example |
| Q58699214 | Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer |
| Q90211749 | Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients |
| Q38671475 | Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative |
| Q34941964 | Phase 0 clinical trials in oncology new drug development |
| Q33985780 | Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies |
| Q28259929 | Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer |
| Q90626481 | Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma |
| Q36680090 | Practices and pitfalls of mouse cancer models in drug discovery. |
| Q84988215 | Preclinical Chemotherapeutic Tumor Models of Common Childhood Cancers: Solid Tumors, Acute Lymphoblastic Leukemia, and Disseminated Neuroblastoma |
| Q26768482 | Preclinical Models for Investigation of Herbal Medicines in Liver Diseases: Update and Perspective |
| Q57043885 | Preclinical Models of Pediatric Brain Tumors-Forging Ahead |
| Q90618474 | Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models |
| Q35996689 | Preclinical Predictors of Anticancer Drug Efficacy: Critical Assessment with Emphasis on Whether Nanomolar Potency Should Be Required of Candidate Agents: TABLE 1 |
| Q39795860 | Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system |
| Q37816960 | Preclinical development of molecular-targeted agents for cancer |
| Q38014543 | Preclinical drug development for childhood cancer |
| Q33619259 | Preclinical efficacy testing for stomach and liver cancers |
| Q39546167 | Preclinical evaluation of the novel multi-targeted agent R1530. |
| Q38112468 | Preclinical models of multiple myeloma: a critical appraisal |
| Q36428208 | Preclinical models of pancreatic ductal adenocarcinoma |
| Q27322080 | Preclinical mouse cancer models: a maze of opportunities and challenges |
| Q50096902 | Preclinical mouse solid tumour models: status quo, challenges and perspectives. |
| Q37311933 | Preclinical screening methods in cancer |
| Q37868449 | Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes |
| Q28252635 | Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer |
| Q35179487 | Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin |
| Q51640753 | Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials |
| Q39631460 | Primary orthotopic glioma xenografts recapitulate infiltrative growth and isocitrate dehydrogenase I mutation |
| Q28083993 | Prioritizing therapeutic targets using patient-derived xenograft models |
| Q99403350 | Promising xenograft animal model recapitulating the features of human pancreatic cancer |
| Q36693061 | Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts |
| Q38024905 | Pulling the plug on a cancer cell by eliminating XIAP with AEG35156 |
| Q30432257 | Questions regarding the predictive value of one evolved complex adaptive system for a second: Exemplified by the SOD1 mouse |
| Q33588711 | Re-adapting T cells for cancer therapy: from mouse models to clinical trials |
| Q28484418 | Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition |
| Q38014542 | Recent developments of transgenic and xenograft mouse models of pancreatic cancer for translational research |
| Q38102104 | Relevance of Animal Models of Pancreatic Cancer and Pancreatitis to Human Disease |
| Q28485035 | Reporting of preclinical tumor-graft cancer therapeutic studies |
| Q36875703 | Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. |
| Q37476480 | Review paper: Implications of the "cancer stem cell" hypothesis on murine models of colon cancer and colitis-associated cancer |
| Q38083980 | Revisiting ovarian cancer preclinical models: Implications for a better management of the disease |
| Q89453574 | SUMO pathway inhibition targets an aggressive pancreatic cancer subtype |
| Q33981293 | Somatic Genetics Empowers the Mouse for Modeling and Interrogating Developmental and Disease Processes |
| Q28080727 | Species differences in tumour responses to cancer chemotherapy |
| Q45324743 | Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program |
| Q36344897 | Statistical inference for tumor growth inhibition T/C ratio |
| Q36554418 | Strategies for optimizing combinations of molecularly targeted anticancer agents |
| Q36874692 | Successful establishment of patient-derived tumor xenografts from gastrointestinal stromal tumor-a single center experience |
| Q33680928 | Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts |
| Q33289822 | Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer |
| Q47753635 | Synthetic Biomaterials to Rival Nature's Complexity-a Path Forward with Combinatorics, High-Throughput Discovery, and High-Content Analysis |
| Q24629614 | Systematic reviews of animal models: methodology versus epistemology |
| Q36187040 | TGF-beta inhibitors for the treatment of cancer |
| Q36786085 | Targeted cancer therapy: promise and reality |
| Q37476433 | Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model |
| Q37010760 | Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis |
| Q39257734 | Targeting Estrogen Receptor-α Reduces Adrenocortical Cancer (ACC) Cell Growthin Vitroandin Vivo: Potential Therapeutic Role of Selective Estrogen Receptor Modulators (SERMs) for ACC Treatment |
| Q54979102 | Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome. |
| Q37694784 | Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation |
| Q52655061 | Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF V600E -mutant melanoma |
| Q99589579 | Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma |
| Q33561078 | Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia |
| Q27314606 | The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy |
| Q37135372 | The ERBB3 receptor in cancer and cancer gene therapy |
| Q98949833 | The Effects of the Alkaloid Tambjamine J on Mice Implanted with Sarcoma 180 Tumor Cells |
| Q36610507 | The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells |
| Q47385759 | The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity |
| Q60320612 | The Plasticity of Stem-Like States in Patient-Derived Tumor Xenografts |
| Q37868024 | The Role of Body-on-a-Chip Devices in Drug and Toxicity Studies |
| Q33607950 | The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma. |
| Q38831340 | The Zebrafish Xenograft Platform: Evolution of a Novel Cancer Model and Preclinical Screening Tool |
| Q33361578 | The future of patient-derived tumor xenografts in cancer treatment |
| Q26851643 | The impact of the myeloid response to radiation therapy |
| Q35081312 | The institutional review board is an impediment to human research: the result is more animal-based research |
| Q36568461 | The mighty mouse: genetically engineered mouse models in cancer drug development |
| Q39552039 | The new 5- or 6-azapyrimidine and cyanuric acid derivatives of l-ascorbic acid bearing the free C-5 hydroxy or C-4 amino group at the ethylenic spacer: CD-spectral absolute configuration determination and biological activity evaluations |
| Q27026705 | The pancreas cancer microenvironment |
| Q48387109 | The pediatric preclinical testing program: description of models and early testing results. |
| Q36863076 | The potential of bioartificial tissues in oncology research and treatment |
| Q92969717 | The role of mouse tumour models in the discovery and development of anticancer drugs |
| Q35801815 | The use of 3-D cultures for high-throughput screening: the multicellular spheroid model |
| Q37851151 | Therapeutic targeting of tumor-stroma interactions. |
| Q53313789 | Timeline: Chemotherapy and the war on cancer |
| Q34025911 | Toward 3D biomimetic models to understand the behavior of glioblastoma multiforme cells |
| Q35033110 | Transforming growth factor-β signalling controls human breast cancer metastasis in a zebrafish xenograft model |
| Q34065785 | Translational considerations for cancer nanomedicine |
| Q50333776 | Translational pancreatic cancer research: A comparative study on patient-derived xenograft models |
| Q38257126 | Translational research in oncology--10 years of progress and future prospects |
| Q38878056 | Translational value of mouse models in oncology drug development |
| Q42117987 | Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response |
| Q42456360 | Transplantation of cancerous cell sheets effectively generates tumour-bearing model mice |
| Q35934478 | Trastuzumab and docetaxel in a preclinical organotypic breast cancer model using tissue slices from mammary fat pad: Translational relevance. |
| Q38830237 | Treatment Efficiency of Free and Nanoparticle-Loaded Mitoxantrone for Magnetic Drug Targeting in Multicellular Tumor Spheroids. |
| Q45865848 | Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus |
| Q52586515 | Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma |
| Q35534811 | Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. |
| Q34892977 | Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest |
| Q89622412 | Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma |
| Q39543143 | Use of the hollow fiber assay for the evaluation of DNA damaging agents. |
| Q37374872 | Use of the in vivo hollow fiber assay in natural products anticancer drug discovery. |
| Q47218248 | Using size-controlled multicellular spheroids of murine adenocarcinoma cells to efficiently establish pulmonary tumors in mice |
| Q46597773 | Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements |
| Q28485360 | What does it take to synergistically combine sub-potent natural products into drug-level potent combinations? |
| Q36028247 | What's wrong with our cancer models? |
| Q37953116 | Xenograft models for preclinical drug testing: Implications for adrenocortical cancer |
| Q36799846 | Xenograft models for the preclinical evaluation of new therapies in acute leukemia |
| Q37332682 | Xenograft models of head and neck cancers |
| Q28538185 | Xenograft tumors vascularized with murine blood vessels may overestimate the effect of anti-tumor drugs: a pilot study |
| Q33622575 | c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. |
Search more.